Catheter ablation in patients with atrial fibrillation and heart failure: is there a light at the end of the tunnel?

Authors: Shpektor A.V.

Company: Cardiology Chair of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of Ministry of Health of the Russian Federation, Delegatskaya ulitsa, 20, stroenie 1, Moscow, 127473, Russian Federation

For correspondence:  Sign in or register.

Type:  Editorial article


For citation: Shpektor A.V. Catheter ablation in patients with atrial fibrillation and heart failure: is there a light at the end of the tunnel? Creative Cardiology. 2019; 13 (1): 5–7 (in Russ.). DOI: 10.24022/1997-3187-2019-13-1-5-7

Received / Accepted:  26.02.2019/03.03.2019

Keywords: atrial fibrillation heart failure catheter ablation drug therapy randomized trials

Полнотекстовая версия:  



The effectiveness of treatment of patients with heart failure accompanied by atrial fibrillation is much lower than in sinus rhythm, which is often impossible to restore and retain medicamentally in this category of patients. Lethality is not reduced, there is a high frequency of drug complications. In the treatment of such patients, the catheter ablation method is of interest, using which, according to a number of randomized studies, the sinus rhythm is more effectively restored and maintained, the total and cardiovascular mortality is significantly reduced (up to 50%), the quality of life is improved.


  1. Roy D., Talajic M., Nattel S., Wyse D.G., Dorian P., Lee K.L. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 2008; 358 (25): 2667–77. DOI: 10.1056/NEJMoa0708789
  2. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., Køber L., Sandøe E., Egstrup K. et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N. Engl. J. Med. 1999; 341 (12): 857–65. DOI: 10.1056/NEJM 199909163411201
  3. Di Biase L., Mohanty P., Mohanty S., Santangeli P., Trivedi C., Lakkireddy D. et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133 (17): 1637–44. DOI: 10.1161/CIRCULATIONAHA.115.019406
  4. Marrouche N.F., Brachmann J., Andresen D., Siebels J., Boersma L., Jordaens L. et al. Catheter ablation for atrial fibrillation with heart failure. N. Engl. J. Med. 2018; 378 (5): 417–27. DOI: 10.1056/NEJMoa1707855
  5. Briceño D.F., Markman T.M., Lupercio F., Romero J., Liang J.J., Villablanca P.A. et al. Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and metaanalysis of randomized controlled trials. J. Interv. Cardiac. Electrophysiol. 2018; 53 (1): 19–29. DOI: 10.1007/s10840-018-0425-0
  6. Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Moretz K. et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial: study rationale and design. Am. Heart J. 2018; 199: 192–9. DOI: 10.1016/ j.ahj.2018.02.015
  7. Golukhova E.Z., Gromova O.I., Bulaeva N.I., Arakelyan M.G., Lifanova L.S., Shlyappo M.A., Aleksandrova S.A., Makarenko V.N. Epicardial fat and atrial fibrillation: the role of profibrinogenic mediators. Kardiologiia. 2018; 58 (7): 59–65. DOI: 10.18087/cardio.2018.7.10145 (in Russ.).
  8. January C.T., Wann L.S., Calkins H. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Heart Rhythm. 2019. DOI: 10.1016/j.jacc.2019.01.011

About Authors

Aleksandr V. Shpektor, Dr Med. Sc., Professor, Head of Department,

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery